[go: up one dir, main page]

CL2015003689A1 - Compuestos derivados de 6-(bencil, heteroaril)aminopirimidina-2,4(1h,3h)-diona y sus sales; composicion farmaceutica que los comprende; y su uso para tratar una cardiomiopatia hipertrofica (hcm) o un trastorno cardiaco que tiene una caracteristica patofisiologica asociada con hcm. - Google Patents

Compuestos derivados de 6-(bencil, heteroaril)aminopirimidina-2,4(1h,3h)-diona y sus sales; composicion farmaceutica que los comprende; y su uso para tratar una cardiomiopatia hipertrofica (hcm) o un trastorno cardiaco que tiene una caracteristica patofisiologica asociada con hcm.

Info

Publication number
CL2015003689A1
CL2015003689A1 CL2015003689A CL2015003689A CL2015003689A1 CL 2015003689 A1 CL2015003689 A1 CL 2015003689A1 CL 2015003689 A CL2015003689 A CL 2015003689A CL 2015003689 A CL2015003689 A CL 2015003689A CL 2015003689 A1 CL2015003689 A1 CL 2015003689A1
Authority
CL
Chile
Prior art keywords
hcm
salts
pharmaceutical composition
aminopyrimidine
dione
Prior art date
Application number
CL2015003689A
Other languages
English (en)
Inventor
Johan Oslob
Robert Anderson
Danielle Aubele
Marc Evanchik
Jonathan Charles Fox
Brian Kane
Puping Lu
Robert Mcdowell
Hector Rodriguez
Yonghong Song
Arvinder Sran
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51177189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003689(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of CL2015003689A1 publication Critical patent/CL2015003689A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

COMPUESTOS DERIVADOS DE PIRIMIDINODIONA Y SUS SALES; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y SU USO PARA TRATAR UNA CARDIOMIOPATIA HIPERTROFICA (HCM) O UN TRASTORNO CARDIACO QUE TIENE UNA CARACTERISTICA PATOFISIOLOGICA ASOCIADA CON HCM.
CL2015003689A 2013-06-21 2015-12-21 Compuestos derivados de 6-(bencil, heteroaril)aminopirimidina-2,4(1h,3h)-diona y sus sales; composicion farmaceutica que los comprende; y su uso para tratar una cardiomiopatia hipertrofica (hcm) o un trastorno cardiaco que tiene una caracteristica patofisiologica asociada con hcm. CL2015003689A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838088P 2013-06-21 2013-06-21
US201461939655P 2014-02-13 2014-02-13
US201461981366P 2014-04-18 2014-04-18

Publications (1)

Publication Number Publication Date
CL2015003689A1 true CL2015003689A1 (es) 2016-10-14

Family

ID=51177189

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003689A CL2015003689A1 (es) 2013-06-21 2015-12-21 Compuestos derivados de 6-(bencil, heteroaril)aminopirimidina-2,4(1h,3h)-diona y sus sales; composicion farmaceutica que los comprende; y su uso para tratar una cardiomiopatia hipertrofica (hcm) o un trastorno cardiaco que tiene una caracteristica patofisiologica asociada con hcm.

Country Status (38)

Country Link
US (9) US9181200B2 (es)
EP (2) EP3702352A1 (es)
JP (5) JP6603213B2 (es)
KR (4) KR20220020410A (es)
CN (2) CN109384729B (es)
AU (5) AU2014281408B2 (es)
BR (1) BR112015031864B1 (es)
CA (1) CA2915967C (es)
CL (1) CL2015003689A1 (es)
CR (1) CR20160032A (es)
CY (2) CY1122964T1 (es)
DK (1) DK3010910T3 (es)
DO (1) DOP2015000300A (es)
EA (2) EA201891009A1 (es)
ES (1) ES2773250T3 (es)
FI (1) FIC20230036I1 (es)
FR (1) FR23C1047I2 (es)
GT (1) GT201500348A (es)
HR (1) HRP20200379T1 (es)
HU (2) HUE047566T2 (es)
IL (7) IL310829A (es)
LT (2) LT3010910T (es)
MX (3) MX2021005326A (es)
MY (1) MY190860A (es)
NL (1) NL301253I2 (es)
NO (1) NO2023043I1 (es)
PE (1) PE20160208A1 (es)
PH (2) PH12021552715A1 (es)
PL (1) PL3010910T3 (es)
PT (1) PT3010910T (es)
RS (1) RS59906B1 (es)
SG (2) SG11201510163TA (es)
SI (1) SI3010910T1 (es)
SM (1) SMT202000071T1 (es)
TN (1) TN2015000553A1 (es)
UA (1) UA117929C2 (es)
WO (1) WO2014205223A1 (es)
ZA (1) ZA201508959B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11414424B2 (en) 2018-08-31 2022-08-16 Cytokinetics, Inc. Cardiac sarcomere inhibitors
US12286437B2 (en) 2021-03-04 2025-04-29 Cytokinetics, Inc. Cardiac sarcomere inhibitors

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103491900B (zh) 2010-12-23 2017-03-01 托尔福公司 用于二尖瓣修复和替换的系统
EP3964176B1 (en) 2011-06-21 2025-05-14 Twelve, Inc. Prosthetic heart valve devices
WO2013059743A1 (en) 2011-10-19 2013-04-25 Foundry Newco Xii, Inc. Devices, systems and methods for heart valve replacement
CN103974674B (zh) 2011-10-19 2016-11-09 托尔福公司 人工心脏瓣膜装置、人工二尖瓣和相关系统及方法
US9039757B2 (en) 2011-10-19 2015-05-26 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US11202704B2 (en) 2011-10-19 2021-12-21 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
ME03654B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PT3105226T (pt) 2014-02-13 2019-11-06 Incyte Corp Ciclopropilaminas como inibidores de lsd1
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
CN106432222A (zh) * 2016-09-19 2017-02-22 丹诺医药(苏州）有限公司 8‑氯‑1‑环丙基‑7‑氟‑9‑甲基‑4‑氧‑4‑氢‑喹嗪‑3‑羧酸酯及其制备方法
CN106946851B (zh) * 2017-03-14 2019-11-12 牡丹江医学院 一种用于预防和治疗肾结石的药物
US10575950B2 (en) 2017-04-18 2020-03-03 Twelve, Inc. Hydraulic systems for delivering prosthetic heart valve devices and associated methods
US10646338B2 (en) 2017-06-02 2020-05-12 Twelve, Inc. Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods
RU2020109345A (ru) * 2017-08-04 2021-09-06 Миокардиа, Инк. Применение мавакамтена для лечения гипертрофической кардиомиопатии
HUE067913T2 (hu) 2018-01-19 2024-11-28 Cytokinetics Inc Dihidrobenzofurán és indén analógok mint szív szarkomer gátlók
US12187712B2 (en) 2018-06-26 2025-01-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
PT3873904T (pt) * 2018-10-29 2024-10-08 Myokardia Inc Compostos de pirimidinadiona bicíclica substituídos por tetra-hidropirano (thp)
WO2020151605A1 (zh) * 2019-01-25 2020-07-30 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
AU2020378197A1 (en) * 2019-11-10 2022-05-26 MyoKardia, Inc. Methods of treatment with myosin modulator
AU2021213748A1 (en) 2020-01-28 2022-08-25 Assia Chemical Industries Ltd. Solid state forms of Mavacamten and process for preparation thereof
CA3190060A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
JP2023550444A (ja) * 2020-11-20 2023-12-01 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 トリアジンジオン系誘導体、その調製方法及びその医薬的応用
CN114539229B (zh) * 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
WO2022111498A1 (zh) * 2020-11-24 2022-06-02 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
WO2022162701A1 (en) * 2021-02-01 2022-08-04 Dr. Reddy's Laboratories Limited Process for preparation of mavacamten and solid state forms thereof
WO2022179611A1 (zh) * 2021-02-25 2022-09-01 南京明德新药研发有限公司 取代的吡啶-2,4-二酮类衍生物
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
IL305234A (en) * 2021-03-17 2023-10-01 Hansoh Bio Llc Nitrogen-containing heterocyclic ketones, preparation methods and medical use thereof
JPWO2023286719A1 (es) * 2021-07-13 2023-01-19
JP7315632B2 (ja) * 2021-09-16 2023-07-26 楽天グループ株式会社 特典付与システム、特典付与方法、及びプログラム
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用
US20250154108A1 (en) * 2022-01-27 2025-05-15 Cms Research & Development Pte. Ltd. Crystal form of 7-azaspiro[4,5]decane-6,10-dione compound and preparation method therefor
WO2023199258A1 (en) 2022-04-13 2023-10-19 Teva Pharmaceuticals International Gmbh Solid state forms of mavacamten and process for preparation thereof
US20250288586A1 (en) 2022-04-26 2025-09-18 MyoKardia, Inc. Methods of Administering Myosin Inhibitors
KR20250012075A (ko) 2022-05-20 2025-01-23 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 트리아진디온계 유도체의 결정형 및 제조 방법
CN119866337A (zh) * 2022-09-16 2025-04-22 江苏豪森药业集团有限公司 一种含氮杂环酮化合物的晶型及其制备方法
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
WO2024218783A1 (en) * 2023-04-17 2024-10-24 Dasha Pharmaceuticals Private Limited Green chemistry approach for synthesis of mavacamten and its intermediate using novel methodology
IT202300016653A1 (it) 2023-08-03 2025-02-03 Olon Spa Processo per preparare mavacamten e intermedio di processo.
WO2025046606A1 (en) 2023-08-26 2025-03-06 Micro Labs Limited Granules of mavacamten for oral administration
WO2025096779A2 (en) 2023-11-01 2025-05-08 Bristol Myers Squibb Company Methods of treatment with a myosin inhibitor using protein levels
WO2025130408A1 (zh) * 2023-12-20 2025-06-26 福石生物科技(合肥)有限公司 一种肌球蛋白抑制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280877B (de) 1960-11-16 1968-10-24 Robugen Gmbh Verfahren zur Herstellung von in 1-Stellung substituierten 4-Aminouracilen
JPS61205261A (ja) 1985-03-08 1986-09-11 Sagami Chem Res Center ６―置換―５―フルオロウラシル誘導体
JPH0637479B2 (ja) * 1987-12-28 1994-05-18 三井東圧化学株式会社 新規ピリミジン誘導体、その製造法およびそれを含有する抗不整脈剤
US5008267A (en) * 1988-10-29 1991-04-16 Mitsui Toatsu Chemicals, Incorporated Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same
JPH03173885A (ja) 1989-12-01 1991-07-29 Mitsui Toatsu Chem Inc ピリミジンジオン誘導体化合物、該化合物の製造法および該化合物を含む抗不整脈剤
FR2659656B1 (fr) 1990-03-15 1994-09-09 Sanofi Sa Derives de pyrimidinedione-2,4 et medicaments les contenant.
JPH0413669A (ja) * 1990-04-27 1992-01-17 Mitsui Toatsu Chem Inc 新規ピリミジンジオン誘導体及び該化合物を含有する抗不整脈剤
JPH06128238A (ja) * 1992-10-20 1994-05-10 Mitsui Toatsu Chem Inc 新規ピリミジンジオン誘導体
EP0697407B1 (en) 1994-08-19 1997-06-25 MITSUI TOATSU CHEMICALS, Inc. Pyrimidinedione derivatives and antiarrhythmic compositions containing same
US5516905A (en) 1994-08-30 1996-05-14 University Of Massachusetts Medical Center Antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections
ATE230733T1 (de) 1998-06-26 2003-01-15 Crompton Vinyl Additives Gmbh Neue nh2-modifizierte 6-aminouracile als stabilisatoren für halogenhaltige polymere
US7416856B2 (en) 1999-05-18 2008-08-26 Cytokinetics, Inc. High sensitivity assay for detection of nucleoside diphosphate production
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
WO2001029010A1 (en) 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
US20030114414A1 (en) 2001-06-15 2003-06-19 Chengxin Zhi Methods for synthesizing substituted pyrimidines
US20030114445A1 (en) 2001-06-15 2003-06-19 Chengxin Zhi N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections
WO2002102769A2 (en) 2001-06-15 2002-12-27 University Of Massachusetts Methods for synthesizing substituted pyrimidines
DE10208460A1 (de) 2002-02-27 2003-09-04 Bayer Ag Uracil-Thioether
ES2283851T3 (es) 2002-08-13 2007-11-01 Warner-Lambert Company Llc Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz.
EA013427B1 (ru) 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB0908193D0 (en) * 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11414424B2 (en) 2018-08-31 2022-08-16 Cytokinetics, Inc. Cardiac sarcomere inhibitors
US11952381B2 (en) 2018-08-31 2024-04-09 Cytokinetics, Inc. Cardiac sarcomere inhibitors
US12275741B2 (en) 2018-08-31 2025-04-15 Cytokinetics, Inc. Cardiac sarcomere inhibitors
US12286437B2 (en) 2021-03-04 2025-04-29 Cytokinetics, Inc. Cardiac sarcomere inhibitors

Also Published As

Publication number Publication date
USRE50050E1 (en) 2024-07-23
IL275837A (en) 2020-08-31
US20170281626A1 (en) 2017-10-05
AU2018264088A1 (en) 2018-12-06
ES2773250T3 (es) 2020-07-10
CN105473576A (zh) 2016-04-06
EP3010910B1 (en) 2020-02-05
CY2023027I1 (el) 2024-02-16
US20160030428A1 (en) 2016-02-04
MX2022014414A (es) 2022-12-07
UA117929C2 (uk) 2018-10-25
EA030846B1 (ru) 2018-10-31
PT3010910T (pt) 2020-02-21
US20140378464A1 (en) 2014-12-25
DK3010910T3 (da) 2020-02-17
DOP2015000300A (es) 2016-03-15
WO2014205223A1 (en) 2014-12-24
JP6980734B2 (ja) 2021-12-15
MX2021005326A (es) 2022-11-17
PH12015502794A1 (en) 2016-03-21
AU2014281408A1 (en) 2016-01-21
FR23C1047I1 (fr) 2024-01-12
HUE047566T2 (hu) 2020-04-28
KR20160026997A (ko) 2016-03-09
GT201500348A (es) 2018-12-20
US9585883B2 (en) 2017-03-07
PH12021552715A1 (en) 2022-05-11
SG11201510163TA (en) 2016-01-28
US20180311242A1 (en) 2018-11-01
CA2915967A1 (en) 2014-12-24
MX2015017865A (es) 2016-09-06
BR112015031864B1 (pt) 2022-02-15
KR102304121B1 (ko) 2021-09-24
NZ715456A (en) 2021-01-29
JP2020019809A (ja) 2020-02-06
RS59906B1 (sr) 2020-03-31
IL323967A (en) 2025-12-01
LTPA2023535I1 (es) 2023-12-27
PE20160208A1 (es) 2016-05-04
FIC20230036I1 (fi) 2023-12-01
MY190860A (en) 2022-05-12
HUS2300042I1 (hu) 2024-01-28
AU2020204271B2 (en) 2022-01-06
CN109384729A (zh) 2019-02-26
AU2020204271A1 (en) 2020-07-16
CY1122964T1 (el) 2021-10-29
AU2022202298A1 (en) 2022-04-28
US20240382486A1 (en) 2024-11-21
EP3010910A1 (en) 2016-04-27
BR112015031864A2 (pt) 2017-07-25
SMT202000071T1 (it) 2020-03-13
IL275837B (en) 2021-09-30
JP6603213B2 (ja) 2019-11-06
JP2025163126A (ja) 2025-10-28
IL243222A0 (en) 2016-02-29
CN105473576B (zh) 2018-10-30
IL302299A (en) 2023-06-01
IL285971A (en) 2021-10-31
CN109384729B (zh) 2023-06-30
ZA201508959B (en) 2022-09-28
KR20220020410A (ko) 2022-02-18
TN2015000553A1 (en) 2017-04-06
MX382520B (es) 2025-03-13
EP3702352A1 (en) 2020-09-02
NO2023043I1 (no) 2023-12-01
AU2024202464A1 (en) 2024-05-02
JP2022036966A (ja) 2022-03-08
EA201690066A1 (ru) 2016-05-31
NL301253I1 (es) 2023-12-13
IL317628A (en) 2025-02-01
FR23C1047I2 (fr) 2024-11-15
SI3010910T1 (sl) 2020-04-30
JP7376556B2 (ja) 2023-11-08
US9181200B2 (en) 2015-11-10
JP2016522263A (ja) 2016-07-28
LTC3010910I2 (es) 2025-08-25
JP2024010108A (ja) 2024-01-23
CY2023027I2 (el) 2024-09-20
PL3010910T3 (pl) 2020-07-27
IL310829A (en) 2024-04-01
US20230165860A1 (en) 2023-06-01
KR20210118470A (ko) 2021-09-30
US20200297726A1 (en) 2020-09-24
KR102359158B1 (ko) 2022-02-08
KR20230144117A (ko) 2023-10-13
EA201891009A1 (ru) 2018-09-28
IL243222B (en) 2020-07-30
HRP20200379T1 (hr) 2020-06-12
AU2014281408B2 (en) 2018-08-16
PH12015502794B1 (en) 2022-09-02
SG10201803459TA (en) 2018-05-30
CA2915967C (en) 2021-07-20
NL301253I2 (nl) 2024-01-10
HK1223930A1 (en) 2017-08-11
CR20160032A (es) 2016-04-01
US20210346379A1 (en) 2021-11-11
LT3010910T (lt) 2020-03-10

Similar Documents

Publication Publication Date Title
CL2015003689A1 (es) Compuestos derivados de 6-(bencil, heteroaril)aminopirimidina-2,4(1h,3h)-diona y sus sales; composicion farmaceutica que los comprende; y su uso para tratar una cardiomiopatia hipertrofica (hcm) o un trastorno cardiaco que tiene una caracteristica patofisiologica asociada con hcm.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
EP3520139A4 (en) ARRANGEMENTS FOR QUANTUM DATA PROCESSING
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
MX382632B (es) Estructura absorbente.
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
UA116920C2 (uk) Інгібітори fgfr4
CL2016000925A1 (es) Inhibidores de bromodominio
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
CR20160419A (es) Nuevos compuestos biciclicos
UY35500A (es) Indazoles sustituidos con heteroarilo
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
MX382747B (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias.
MX386298B (es) Composicion farmaceutica que comprende adalimumab.